ClinicalTrials.gg
RecruitingNCT06916481PHENOMENONUpdated Nov 24, 2025

Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures

An observational study in Community Acquired or Acquiring Hospital Acquired Pneumonia, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Pneumonia by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 4 under way, none of them phase 3. Pneumonia · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
4th of 12
300 · median 160
Started
2025
with 3 others
Observational
12 of 23
3 open now
Registered
21st of 23
by date

Among the 23 studies in Pneumonia by Assistance Publique - Hôpitaux de Paris, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, and was the 21st registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

3 of the 23 studies in Pneumonia by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Pneumonia by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Background: Pneumonia remains a leading cause of antibiotic consumption globally, contributing significantly to the burden of antimicrobial resistance (AMR). The respiratory microbiome plays a crucial role in the emergence of AMR and therapeutic failure in both community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). The PHENOMENON study aims to investigate the relationship between the respiratory microbiome composition and clinical outcomes to improve the prediction of treatment failure and AMR emergence.

Methods: This multicenter prospective cohort study will include 300 adult patients across three cohorts: CAP in general wards, severe CAP in intensive care units (ICU), and ventilator-associated HAP (vHAP/VAP). Patients will undergo oropharyngeal and rectal swabbing at admission (Day 0), Day 3, Day 7-10, and Day 90, along with blood sampling and endotracheal aspirates in intubated patients. The primary objective is to assess the association between baseline respiratory microbiome composition and time to antibiotic response within 7-10 days. The composite primary endpoint includes clinical failure, microbiological failure, or AMR emergence. Secondary endpoints explore the association between microbiome composition and pneumonia recurrence, severity, hospital length of stay, and mortality at Day 28 and Day 90.

Expected Outcomes: This study will provide insights into the predictive value of respiratory microbiome composition on antibiotic response and AMR emergence. Understanding these relationships may guide personalized antibiotic strategies and optimize pneumonia management, ultimately reducing treatment failure rates and improving patient outcomes.

Read the detailed description

Pneumonia can be acquired in the community such as COVID-19 or flu, or during hospitalization for a different medical condition.

The significant burden of CAP is set to increase with ageing populations and growing rates of comorbidity. CAP was the leading cause of communicable diseases and the second cause of disability-adjusted life-years loss in the world in 2019, even before the COVID-19 pandemic (GBD 2019 Adolescent Mortality Collaborators 2021; GBD 2019 Diseases and Injuries Collaborators 2020). CAP is classically induced by virulent bacteria (such as Streptococcus pneumoniae) or viruses (influenza), but also new pathogenic viruses such as SARS-CoV-2 (COVID-19).

Incidence of VAP ranges from 5% to 67% depending on case mix and diagnostic criteria. In the US, the incidence of VAP ranges from 2 to 16 episodes per 1,000 ventilator-day. The estimated risk of VAP is initially high and decreases to less than 0.5% per day after 14 days of mechanical ventilation. VAP increases the duration of hospitalization by 7 days and health-care costs by approximately $40,000 USD per episode (Safdar et al. 2005; Eber et al. 2010). Antimicrobial resistance is rising, leading to increased durations of hospital stay and excess deaths in septic patients worldwide. The World Health Organization considers antibiotic resistance to be one of the biggest global health threats we are currently facing. AMR, including malaria, tuberculosis and bacterial infections, may increase to 10 million fatalities worldwide by 2050. While some resistance is intrinsic in some bacterial taxa, the main issue is acquired resistance, as bacteria can exchange genetic material and thereby spread antibiotic resistance genes (ARG).

Previous carriage of extended-spectrum beta-lactamases-producing Enterobacterales (ESBL-E) is found in 5 to 25% of ICU patients. Although a previous carriage is the major risk factor associated with VAP related to ESBL-E, only 5% to 20% of the ESBL-E carriers will develop a VAP related to ESBL-E. Carriage status therefore has a high negative predictive value for ESBL-E-associated VAP, whereas positive predictive value, i.e., the probability of having an ESBL-E infection in case of ESBL-E carriage, is less than 50%.

When caring for patients with VAP, recent studies have shown that the adequacy of the initial antimicrobial therapy is not associated with a significant improvement of VAP prognosis, especially if a multidrug-resistant (MDR) Gram-negative bacterium is involved (Sommer et al. 2018; Titov et al. 2021). One likely explanation of the absence of benefit of adequate therapy within 24h is the rapid diffusion and expression of ARGs within the microbiome during treatment. It has been demonstrated the feasibility of characterizing lung microbiota by producing preliminary data from 174 respiratory samples collected in 65 patients included in the IBIS biobank within the IBIS cohort. These preliminary analyses have also confirmed that the respiratory microbiome of hospitalized patients shifts from a normal composition (day 1) to a specific pattern poor in Streptococcus and enriched in Haemophilus (day 7). Recently, it was observed in a randomized clinical trial that probiotics increase the ARG richness of the gut microbiome during antimicrobial treatment (Figure 2) (Montassier et al. 2021). These data demonstrated the ability to investigate the time course of ARG during treatment in human samples, and reinforce the hypothesis of rapid modifications of the ARG during treatment.

In summary, treatment failures are common in patients with CAP and HAP, even in cases of adequate antimicrobial therapy. Some specific antimicrobial therapies result in better outcomes than standard of cares and classical microbiology fail to explain this outcome.

Recent data demonstrated that the microbiome is a significant source of antibiotic resistance genes (ARG) which can rapidly be diffused between species during treatment.

In light of these preliminary results, we intend

  1. to define VAP and CAP sub-phenotypes based on the real-time course of the load of ARG in vivo
  2. to demonstrate in vivo that specific microbiome editing based on these phenotypes can enhance pneumonia outcomes.

The definition of these phenotypes of pneumonia is likely to impact the way patients are treated in daily practice, shifting the antimicrobial treatment from in vitro functional tests to in vivo prediction of response to treatment.

03

Conditions studied

  • Community Acquired or Acquiring Hospital Acquired Pneumonia

Browse trials for

Keywords

  • Pneumonia, respiratory microbiome, antibiotic treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The population of interest is specific to each cohort. > For cohort 1: patients will be informed orally and in writing by the investigator on the delegation log during their hospitalization before inclusion. Patients will be informed of their right to decline participation and an informed written consent will be obtained by the investigator for biobank collection. > For cohorts 2 and 3: some patients may not be able to decline participation (sedated, ventilated). In these cases, relatives, if they are present, will be informed orally and in writing by the investigator on the delegation log. Relatives will be informed of their right to decline participation on behalf of the patient. Patients will be informed as soon as their health allows it. Patients will be informed of their right to decline to continue, and of their right to forbid the use of already collected data and/or samples.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1: CAP at emergency department and requiring hospitalization in general wards :

    • Age ≥18 years
    • Hospitalization in a medical department (not ICU)
    • Presence of at least one acute clinical sign compatible with pneumonia (e.g. dyspnea, cough, purulent sputum or purulent tracheal aspirations or crackles), and temperature above 38°C in the 48 hours prior to inclusion
    • AND new pulmonary infiltrate on chest X-ray or CT scan (on Day 0 or within three days of inclusion)
    • Efficient treatment initiated for less than 24 hours
    • Sputum collection possible
  • Cohort 2: Severe CAP with ICU hospitalization :

    • Age ≥18 years
    • Hospitalization in intensive care unit for at least 24 hours.
    • Presence of at least one acute clinical sign compatible with pneumonia (e.g. dyspnoea, cough, purulent sputum or crackles), temperature greater than 38°C in the 48 hours prior to hospital admission
    • AND new pulmonary infiltrate on chest X-ray or CT scan (on Day 0 or within three days of inclusion)
    • Efficient treatment initiated for less than 24 hours
    • Sputum collection or tracheal aspiration or any distal bacterial sample (BAL, plugged telescopic catheter) collection possible
  • Cohort 3: vHAP or VAP :

    • Age ≥18 years
    • vHAP: mechanical ventilation, in a patient previously hospitalized for more than 48 hours at the onset of new or worsening radiological infiltrates and 2 of the following: fever or hypothermia, leukocytosis > 12 G/L or leukopenia \< 4G/L, purulent tracheal aspirates,
    • VAP: mechanical ventilation for more than 48 hours, new or worsening radiological infiltrates and 2 of the following: fever (>38°C) or hypothermia (\<36.5°C) in the 24 hours prior to inclusion, leucocytosis> 12 G/L or leukopenia \< 4G/L, purulent tracheal aspirates
    • AND plugged telescopic catheter (PTC) ≥103colony-forming units (CFU)/ml or bronchoalveolar lavage (BAL) culture ≥104 CFU/ml or purulent tracheal aspirates ≥ 106 UFC/mL
    • AND treated with active antibiotic therapy for pneumonia for less than 24 hours

Exclusion criteria

Exclusion Criteria:

  • Cohort 1: CAP with hospitalization in general wards :

    • AIDS
    • Patient on high-dose >2 mg/kg prednisone equivalent
    • Bone marrow transplant patients
    • Cancer patients undergoing chemotherapy within 3 months of inclusion
    • Opposition of the patient (absence of informed written consent)
    • Scheduled transfer to another hospital
    • Patient under guardianship or comparable legal status
    • NB: Patients included in the cohort 1 and referred to ICU within the first 24 hours will be included in the cohort 2.
  • Cohort 2: Severe CAP with ICU hospitalization :

    • AIDS
    • Patient on high-dose corticosteroids >2 mg/kg prednisone equivalent
    • Bone marrow transplant patients
    • Cancer patients undergoing chemotherapy within 3 months of inclusion
    • Stays shorter than 24h in the ICU will be exlcuded
    • Absence of informed written consent of the patient if they are fit, or absence of informed written consent of the relative/caregiver (for patients unable to understand the information and in the absence of a relative/caregiver, emergency inclusion is authorized)
    • Decision to forego life-sustaining therapy
    • Patient under guardianship or comparable legal status
  • Cohort 3: vHAP or VAP :

    • AIDS
    • Patient on high-dose corticosteroids >2 mg/kg prednisone equivalent
    • Bone marrow transplant patients
    • Cancer patients undergoing chemotherapy within 3 months of inclusion
    • Absence of informed written consent of the patient if he is fit, or absence of informed written consent of the relative (for patients unable to understand the information and in the absence of a relative, emergency inclusion is authorized)
    • Decision to forego life-sustaining therapy
    • Patient under guardianship or comparable legal status
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort 1 : community acquired pneumonia (CAP) hospitalized in the ward

    Cohort 1 (CAP hospitalized in the ward) is a group with or without antibacterial exposure with few parameters interfering with the microbiota composition except for the present infection.

  • Cohort 2 : CAP in intensive care unit (=ICU)

    Cohort 2 (CAP in ICU) is a very severe subgroup always exposed to antibacterial agent during the pneumonia and other medications (or processes) interfering with microbiota composition during treatment.

  • Cohort 3: acquiring hospital acquired pneumonia that needs invasive ventilation (=vHAP or VAP)

    Cohort 3 (vHAP or VAP) is a very severe subgroup of patients exposed to broad spectrum antibacterial agents and other medications interfering with microbiota composition. Intubation required endotracheal aspirates during the current care and will allow comparison of the microbiota composition in the oropharynx and in the trachea.

06

What researchers measure

Primary outcomes

  1. To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.

    The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) Clinical success is defined as : \- vHAP-VAP: resolution of the clinical symptoms that lead to the diagnosis on vHAP/VAP

    Time frame: 3 months

  2. To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.

    The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) Clinical success is defined as : \- CAP: resolution of fever and dyspnea, or oxygen therapy requirement clinical symptoms

    Time frame: 3 months

  3. To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.

    The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure Microbiological failure is defined as: \- Persistence in standard culture of respiratory samples, of the microorganisms causing the pneumonia, independently from antibiotic susceptibility

    Time frame: 3 months

  4. To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.

    The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure OR Microbiological failure is defined as: Appearance, on respiratory sample, of a new pathogen considered as requiring a new antimicrobial therapy (superinfection) by the attending physician, before the test-of-cure visit (day 7-10).

    Time frame: 3 months

  5. To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.

    The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion. Antibiotic resistance is defined as one of the 3 following definitions: \- Detection of the same pneumonia pathogen but with resistance to at least one of the given antibiotics, on any respiratory sample collected after initial diagnosis;

    Time frame: 3 months

  6. To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.

    The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion. Antibiotic resistance is defined as one of the 3 following definitions: \- Occurrence of a new pathogen in respiratory specimens resistant to at least one of the given antibiotics;

    Time frame: 3 months

  7. To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.

    The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion. Antibiotic resistance is defined as one of the 3 following definitions: \- Occurrence of a new pathogen in another site (infection, colonization or carriage) resistant the given antibiotic(s).

    Time frame: 3 months

Secondary outcomes

  1. Pneumonia relapse or recurrence

    Pneumonia relapse or recurrence

    Time frame: 3 months

  2. Time to clinical recovery (regardless of microbiological recovery or resistance failure)

    To investigate the link between the composition of the respiratory microbiome at the start of treatment and pneumonia recurrence (second episode of pneumonia with at least one common pathogen)

    Time frame: 3 months

  3. Time to clinical recovery (regardless of microbiological recovery or resistance failure)

    To investigate the link between the composition of the respiratory microbiome at the start of treatment and pneumonia relapse (second episode of pneumonia with new pathogens)

    Time frame: 3 months

  4. Presence or absence of antimicrobial resistance at any point during follow-up

    To study the link between the composition of the respiratory microbiome at the start of treatment and the emergence of antibiotic resistance

    Time frame: 3 months

  5. Association between specific antibiotics and respiratory microbiome evolution

    To study the link between the antibiotic regimen (spectrum and dose) and time course of the respiratory microbiome composition and resistome

    Time frame: 3 months

  6. Association between specific antibiotics and gut microbiome evolution

    To study the link between the antibiotic regimen (spectrum and dose) and time course of the gut microbiome composition and resistome

    Time frame: 3 months

  7. Duration of antimicrobial treatment

    Duration of antimicrobial treatment

    Time frame: 3 months

  8. Association between baseline microbiome and Acute Respiratory Distress Syndrome during pneumonia

    To evaluate the link between the respiratory microbiome on baseline and Pneumonia severity (ARDS yes or no)

    Time frame: 3 months

  9. Association between baseline microbiome and Length of initial hospital stay/ ICU stay

    To evaluate the link between the respiratory microbiome on baseline and the length of hospital stay/ ICU stay after the start of antimicrobial treatment

    Time frame: 3 months

  10. Association between baseline microbiome and All-cause mortality on day 28 and day 90

    To evaluate the link between the respiratory microbiome on baseline and all-cause mortality on day 28 and day 90 after the start of antimicrobial treatment

    Time frame: 3 months

  11. Quality of life questionnaires (EQ-5D-5L) on day 0, day 28 and day 90

    To assess the quality of life on day 28 and day 90 after the start of antimicrobial therapy

    Time frame: 3 months

  12. Correlation between oropharyngeal, endotracheal and gut microbiota profiles in intubated patients

    To validate in intubated patients the relationship between oropharyngeal, endotracheal and gut microbiota profiles.

    Time frame: 3 months

07

Study locations

1 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.

Of 210 non-industry observational studies under Pneumonia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 22 months is below that.

Counting every sponsor, half of 223 studies reached it within 27 months; a quarter within 13 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Sep 15, 2027
CompletionEst.
Sep 15, 2028
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06916481
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Nov 6, 2025
Primary completion
Sep 15, 2027 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Nov 24, 2025

Study contacts

Jean-françois TIMSIT, MD, PHD
Contact
jean-françois.timsit@aphp.fr
+ 33 1 40 25 77 07
Antoine Roquilly, MD, PHD
Contact
Antoine.ROQUILLY@chu-nantes.fr
+33 2 53 48 22 30

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion